

Phase III study evaluating the efficacy of Drogenil in pancreatic carcinoma

Submission date 19/08/2002	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 19/08/2002	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 30/10/2019	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number
NHS_1

Study information

Scientific Title
Phase III study evaluating the efficacy of Drogenil in pancreatic carcinoma

Study objectives
Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Carcinoma of the pancreas

Interventions

1. Group A: Flutamide 250 mg three times daily
2. Group B: Placebo

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Drogenil (flutamide)

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

31/01/1997

Eligibility**Key inclusion criteria**

Not provided at time of registration

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1995

Date of final enrolment

31/01/1997

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

MRC Clinical Trials Unit

London

United Kingdom

NW1 2DA

Sponsor information**Organisation**

Schering-Plough Ltd (UK)

ROR

<https://ror.org/00148fb49>

Funder(s)**Funder type**

Industry

Funder Name

Schering-Plough Ltd (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	presumed results	27/06/1998	30/10/2019	Yes	No